Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods

Chemotherapy

Volumn 52, Issue 4, 2006, Pages 190-195

  Somasundaram, Sulochana ^a   Paramasivan, N Chinnambedu ^a,b  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Gatifloxacin; Moxifloxacin; Mycobacterium tuberculosis

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE;

7H11 AGAR MEDIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEC RADIOMETRY; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; GROWTH INHIBITION; INTERMETHOD COMPARISON; LOEWENSTEIN MEDIUM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROPORTION SUSCEPTIBILITY TESTING METHOD; TECHNIQUE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES;

EID: 33745107614     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093486     Document Type: Article

References (24)

1. Telzak EE: Tuberculosis and human immunodeficiency virus infection. Med Clin North Am 1997;81:345-359.
2. Venkataraman P, Paramasivan CN, Prabhakar R: In vitro activity of ciprofloxacin and ofloxacin against South Indian isolates of Mycobacterium tuberculosis. Indian J Tuberc 1994;41:87-90.
3. Grasela DM: Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin Infect Dis 2000;31:S51-S58.
4. Stass H, Dalhoff A, Kubitza D, Schuhly U: Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42:2060-2065.
5. Mignot A, Guillaume M, Brault M, Gualano V, Millerioux L, Gohler K, Stahlberg HJ: Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers. Chemotherapy 2002;48:116-121.
6. Mignot A, Guillaume M, Gohler K, Stahlberg HJ: Oral bioavailability of gatifloxacin in healthy volunteers under fasting and fed conditions. Chemotherapy 2002;48:111-115.
7. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH: The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168: 1342-1345.
8. Pletz MWR, Roux AD, Roth A, Neumann KH, Mauch H, Lode H: Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-782.
9. Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison DA: Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:627-631.
10. Alvirez-Freites EL, Carter JL, Cynamon MH: In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:1022-1025.
11. Yoshimatsu T, Nuermberger EL, Tyagi S, Chaisson R, Bishai WR, Grosset J: Bactericidal activity of increasing daily and weekly doses of moxifloacin in murine tuberculosis. Antimicrob Agents Chemother 2002;46:1875-1879.
12. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-426.
13. Sulochana S, Venkataraman P, Paramasivan CN: Evaluation of various methods of susceptibility to ofloxacin in strains of Mycobacterium tuberculosis. Indian J Med Res 1999;110: 186-189.
14. National Committee for Clinical Laboratory Standards: Susceptibility testing of Mycobacteria, Nocardia and other aerobic Actinomycetes. NCCLS document. Wayne, NCCLS, 2003, M24-A23, No18, pp 1-71.
15. Jensen KA: Towards a standardization of laboratory methods. Second report of the sub-committee of laboratory methods of the international union against tuberculosis. Bull Int Union Tuberc 1955;25:89-104.
16. Cohn ML, Waggoner RF, McClatchy JK: The 7H11 medium for the cultivation of mycobacteria. Am Rev Respir Dis 1968;98:295-296.
17. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA: Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969;41:21-43.
18. Kent PT, Kubica GP: Antituberculosis Chemotherapy and Drug Susceptibility Testing in Public Health Mycobacteriology: A Guide for Level III Laboratory. Atlanta, Centers for Disease Control, 1985, pp 159-184.
19. Siddiqi SH: BACTEC 460 TB system; in: Product and Procedure Manual, Revision D. Sparks, Becton Dickinson Microbiology Systems, 1995, Sec IV, pp 1-13.
20. Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, Kornblum J, Laszlo J, Roberts G, Salfinger M, Wittwer F, Siddiqi SH: Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999;37:3179-3186.
21. Sulochana S, Rahman F, Paramasivan CN: In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005; 17:169-173.
22. Garcia-Tapia A, Rodriguez JC, Ruiz M, Royo G: Action of fluoroquinolones and linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis. Chemotherapy 2004;50:211-213.
23. US Pharmacist: Review of New Drug in US Pharmacist Continuing Education, ACPE Program No 430-000-00-030-H01, Oct 2002.
24. Stass H, Kubitza D, Halabi A, Delesen H: Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002;53:232-237.